{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-015364","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.245322+00:00","generated_at":"2026-05-26T09:27:09.639114+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Estrella Immunopharma receives Buy rating from D. Boral Capital with $16 price target","bullets":["D. Boral Capital initiates coverage on Estrella (ESLA) with a Buy rating and 12-month price target of $16.00 per share.","Lead candidate EB103, a CD19/CD22-targeted ARTEMIS® T-cell therapy, is in Phase I/II trials for B-cell Non-Hodgkin's Lymphoma.","D. Boral Capital's valuation model assumes 30% probability of success and a 30% discount rate.","D. Boral Capital will also provide investment banking services, creating a potential conflict of interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-015364","json":"https://secwatch.observer/filing/0001213900-25-015364.json","markdown":"https://secwatch.observer/filing/0001213900-25-015364.md","text":"https://secwatch.observer/filing/0001213900-25-015364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025015364/0001213900-25-015364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025015364/ea0231621-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T09:27:09.639114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}